Transgene

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40
Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 267
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 109
Contact:

Re: Transgene

Berichtdoor And its gone! » 18 Jul 2019 10:21

TRANSGENE (TNG)
Chemical/Pharmaceutical/Health

ISIN: FR0005175080

LAATSTE
(18/07/19 - 10:21)
2,34
WIJZIGING
(-0,04)
-1,68%

Van kwaad naar erger :? KV prijs is bereikt.
Wel hoger volume dan de voorbije dagen.



powered by Surfing Waves

Marbull
Forum verkenner
Forum verkenner
Berichten: 59
Lid geworden op: 17 Sep 2018 16:14
waarderingen: 9
Contact:

Re: Transgene

Berichtdoor Marbull » 18 Jul 2019 11:09

And its gone! schreef:TRANSGENE (TNG)
Chemical/Pharmaceutical/Health

ISIN: FR0005175080

LAATSTE
(18/07/19 - 10:21)
2,34
WIJZIGING
(-0,04)
-1,68%

Van kwaad naar erger :? KV prijs is bereikt.
Wel hoger volume dan de voorbije dagen.


Los erdoor aan t zakken, top !!

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 267
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 109
Contact:

Re: Transgene

Berichtdoor And its gone! » 18 Jul 2019 12:55

Marbull schreef:
And its gone! schreef:TRANSGENE (TNG)
Chemical/Pharmaceutical/Health

ISIN: FR0005175080

LAATSTE
(18/07/19 - 10:21)
2,34
WIJZIGING
(-0,04)
-1,68%

Van kwaad naar erger :? KV prijs is bereikt.
Wel hoger volume dan de voorbije dagen.


Los erdoor aan t zakken, top !!


Order geplaatst onder de 2.3. Let's see :wtf:

Marbull
Forum verkenner
Forum verkenner
Berichten: 59
Lid geworden op: 17 Sep 2018 16:14
waarderingen: 9
Contact:

Re: Transgene

Berichtdoor Marbull » 18 Jul 2019 13:02

2,28 dadelijk.. :roll:

Gebruikersavatar
And its gone!
Forum actieveling
Forum actieveling
Berichten: 267
Lid geworden op: 30 Mei 2018 21:25
waarderingen: 109
Contact:

Re: Transgene

Berichtdoor And its gone! » 18 Jul 2019 13:47

Marbull schreef:2,28 dadelijk.. :roll:


Jaja na een aantal weken lichte schommelingen wordt er nu aan de boom geschud.

TRANSGENE (TNG)
Chemical/Pharmaceutical/Health

ISIN: FR0005175080

LAATSTE
(18/07/19 - 13:45)
2,295
WIJZIGING
(-0,085)
-3,57%
BID
2,29
ASK
2,315

Behremoth
Forum newbie
Forum newbie
Berichten: 10
Lid geworden op: 20 Aug 2018 18:04
waarderingen: 16
Contact:

Re: Transgene

Berichtdoor Behremoth » 18 Jul 2019 18:51

Transgene Receives MHRA Approval for a Clinical Trial
of TG6002, a Next-generation Oncolytic Virus,
Administered by Intrahepatic Artery Infusion
in Patients with Colorectal Cancer with Liver Metastases


TG6002 has multiple mechanisms of action for enhanced anti-tumor activity: oncolysis,
local production of chemotherapy in tumor and cell-mediated immune response
The Phase 1/2a trial is expected to start in Q4 2019
Strasbourg, France, July 18, 2019, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company
that designs and develops virus-based immunotherapies for the treatment of solid tumors, today
announces it has received the approval from the UK Medicines and Healthcare Products Regulatory
Agency (MHRA) to proceed with a Phase 1/2a clinical trial of TG6002 administered by intrahepatic artery
(IHA) infusion in colorectal cancer patients with unresectable liver metastases (CRLM).

TG6002 is a next-generation oncolytic virus (OV), which has multiple mechanisms of action. It has been
engineered to combine the killing of cancer cells (oncolysis), the production of 5-FU, a widely used
chemotherapeutic agent, in the tumor site, and the eliciting of an immune response against tumor cells.
TG6002 expresses the proprietary FCU1 gene in the cancer cells it has infected, leading to local conversion
of the pro-drug 5-FC (administered orally) into 5-FU. This is particularly important as most gastrointestinal
tumors are 5-FU sensitive. TG6002 has been shown to induce both response in the primary tumor and an
immune-mediated regression of distant metastases in preclinical experiments1
.
“Current systemic therapies prolong survival of CRLM patients at the cost of significant side effects. We
believe that TG6002 therapy administered via an IHA infusion potentially offers an additional effective
and well tolerated treatment modality for these difficult to treat patients. By administering it via the
intrahepatic artery, we believe we can conveniently deliver more concentrated doses of TG6002 to the
tumor, to achieve better outcomes for unresectable colorectal cancer, whilst limiting systemic exposure.
In parallel, Transgene is conducting a Phase 1/2 trial to investigate TG6002 in colorectal cancer patients
when given intravenously,” said Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene.
Dr. Adel Samson, MB ChB PhD, Medical Oncologist at St. James’ University Hospital, is the Chief
Investigator of the trial.

This trial is a single-arm open-label Phase 1/2a trial evaluating the safety, pharmacokinetics and efficacy
of repeated and ascending doses of TG6002 administered by IHA route in combination with oral 5-FC, a
non-cytotoxic pro-drug that can be converted in 5-FU. The study is expected to start in Q4 2019 and could
enroll up to 75 patients.
And its gone! liked last!

Marbull
Forum verkenner
Forum verkenner
Berichten: 59
Lid geworden op: 17 Sep 2018 16:14
waarderingen: 9
Contact:

Re: Transgene

Berichtdoor Marbull » 18 Jul 2019 19:14

And its gone! liked last!

Stofke
Premiummember
Premiummember
Berichten: 694
Lid geworden op: 13 Okt 2017 16:18
waarderingen: 357
Contact:

Re: Transgene

Berichtdoor Stofke » 19 Jul 2019 00:15

Stofke schreef:
Stofke schreef:Transgene (Euronext: TNG),
onderdeel van Institut Mérieux, is een beursgenoteerd Frans biotechnologiebedrijf dat zich richt op het ontwerpen en ontwikkelen van gerichte immunotherapieën voor de behandeling van kankers en infectieziekten. Transgen's programma's maken gebruik van virale vectortechnologie met het doel om geïnfecteerde of kankercellen indirect of direct te doden.
De belangrijkste klinische fase van het bedrijf zijn: TG4010 voor niet-kleincellige longkanker, Pexa-Vec voor leverkanker en TG4001 voor HPV-positieve hoofd- en halstumoren. Het bedrijf heeft verschillende andere programma's in klinische en preklinische ontwikkeling.
Transgene is ook eigenaar van Invir.IOTM, een nieuw technologieplatform dat zich toelegt op het ontwerp van de volgende generatie oncolytische virussen. Deze multifunctionele virussen zijn gericht op het moduleren van de micro-omgeving van de tumor.
Het bedrijf is gevestigd in Straatsburg, Frankrijk, en heeft aanvullende activiteiten in Lyon, China en de Verenigde Staten.

Hieronder nog een stukje uit Beursbrink van 22 mei 2018

Ook Transgene (ticker: TNG en ISIN-code FR0005175080) is een naam om in de gaten te houden. Het bedrijf, voor 52% in handen van het instituut Mérieux, is actief op het vlak van kankeronderzoek en heeft een zeer rijke onderzoeksportefeuille. Transgene heeft maar liefst 9 middelen in klinische onderzoeksfase waaronder TG4010 tegen longkanker en TG4001 tegen bepaalde types van hoofd- en nekkanker. De meeste van de middelen van Transgene moeten reeds bestaande geneesmiddelen doeltreffender maken. TG4010 wordt samen met Opdivo van Bristol-Myers Squibb gebruikt. De resultaten van deze studie worden later dit jaar gepubliceerd. Recent haalde de groep €14,4 miljoen op waardoor het zeker nog anderhalf jaar verder kan.

Voor meer info zie https://www.transgene.fr/


Op 28mei had Mérieux 52% van de aandelen in handen, ik keek zopas even op de site en dit is ondertussen 57% geworden.


Ondertussen zit Mérieux aan 60%. De free float wordt dus alsmaar kleiner.
Marbull liked last!

Marbull
Forum verkenner
Forum verkenner
Berichten: 59
Lid geworden op: 17 Sep 2018 16:14
waarderingen: 9
Contact:

Re: Transgene

Berichtdoor Marbull » 19 Jul 2019 11:24

BREAKING: Important News On TRANSGENE (TNG) (2019-07-18)
July 18, 2019 Anthony Rankin 0 Comments
Our first news is that we’ve found some terrific services that we believe will help immensely if you are trading TRANSGENE – take a quick look through the following:

Beat The Market Analyzer: http://currencydispatch.com/recommended ... -investors (this is a fantastic tool – use this to analyze TRANSGENE in much more depth)
MM Publishing: http://currencydispatch.com/mmpublishin ... -investors
Trading Code: http://currencydispatch.com/tradingcode ... -investors
Trader HR: http://currencydispatch.com/traderHR-for-TNG-investors

REPORTING FOR 2019-07-18 | CURRENCYDISPATCH.COM: We have conducted a deep analysis of how TRANSGENE has been trading over the last 2 weeks and the past day especially. On its latest session, TRANSGENE opened at 2.41, reaching a high of 2.41 and a low of 2.37 before closing at a price of 2.38. There was a total volume of 31484.0.

VOLUME INDICATORS: We saw an accumulation-distribution index of -9728.6, an on-balance volume of 7985.0, chaikin money flow of -0.06 and a force index of -273.68. There was an ease of movement rating of -0.0, a volume-price trend of -700.61 and a negative volume index of 1041.9.

VOLATILITY: We noted an average true range of 0.06, bolinger bands of 2.5, an upper bollinger band of 2.37, lower bollinger band of 2.43, a bollinger high band indicator of 0.0, bollinger low band indicator of 0.0, a central keltner channel of 2.42, high band keltner channel of 2.48, low band keltner channel of 2.36, a high band keltner channel indicator of 0.0 and a low band keltner channel indicator of 0.0. There was a donchian channel high band of 2.5, a donchian channel low band of 2.38, a donchian channel high band indicator of 0.0, and a donchian channel low band indicator of 0.0.

TREND: We calculated a Moving Average Convergence Divergence (MACD) of -0.01, a MACD signal of -0.0, a MACD difference of -0.0, a fast Exponential Moving Average (EMA) indicator of 2.42, a slow Exponential Moving Average (EMA) indicator of 2.43, an Average Directional Movement Index (ADX) of nan, an ADX positive of 20.0, an ADX negative of 20.0, a positive Vortex Indicator (VI) of 0.93, a negative VI of 1.04, a trend vortex difference of 0.11, a trix of -0.04, a Mass Index (MI) of 16.12, a Commodity Channel Index (CCI) of -136.62, a Detrended Price Oscillator (DPO) of 0.05, a KST Oscillator (KST) of -3.36 and a KST Oscillator (KST Signal) of 2.15 (leaving a KST difference of -5.51). We also found an Ichimoku rating of 2.4, an Ichimoku B rating of 2.41, a Ichimoku visual trend A of 2.43, an Ichimoku visual trend B of 2.44, an Aroon Indicator (AI) up of 16.0 and an AI indicator down of 64.0. That left a difference of -48.0.

MOMENTUM: We found a Relative Strength Index (RSI) of 32.97, a Money Flow Index (MFI) of 53.75, a True Strength Index (TSI) of 0.93, an ultimate oscillator of 47.58, a stochastic oscillator of 36.17, a stochastic oscillator signal of 48.23, a Williams %R rating of -63.83 and an awesome oscillator of -0.02.

RETURNS: There was a daily return of -1.24, a daily log return of -1.25 and a cumulative return of -2.46.

What the heck does all of this mean? If you are new to technical analysis, the above may be gibberish to you, and that’s OK (though we do advise learning these things). The bottom line is that AS OF 2019-07-18 (if you are reading this later, the analysis will be out of date), here is what our deep analysis of technical indicators are telling us for TRANSGENE…

Gillepils
Forum actieveling
Forum actieveling
Berichten: 890
Lid geworden op: 25 Aug 2016 08:48
waarderingen: 264
Contact:

Re: Transgene

Berichtdoor Gillepils » 22 Jul 2019 11:23

Marbull schreef: The bottom line is that AS OF 2019-07-18 (if you are reading this later, the analysis will be out of date), here is what our deep analysis of technical indicators are telling us for TRANSGENE…


De clou ontbreekt :roll:

Tijdelijke promo tot 31 augustus:




Word gratis lid op Beursig.com

Discussieer met duizenden beleggers, profiteer van minder advertenties, ideaal voor smartphone, betere gebruikservaring en abonneer op uw favoriete onderwerpen.

Registreer nu binnen enkele tellen